Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

OCRX 3.74 -0.11 (-2.86%)
price chart
Ocera (formerly Tranzyme) extends cash runway with $20M debt facility
Drug developer Ocera Therapeutics, Inc. (Nasdaq: OCRX) could borrow up to $20 million, extending the company's cash runway into at least mid-2017.
Ocera Therapeutics Secures $20 Million Debt Facility from Oxford Finance and ...
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., July 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today ...
Ocera Therapeutics, Inc. (OCRX) Files Form 4 Insider Buying : Wendall Wierenga ...
Ocera Therapeutics, Inc. (OCRX): Wendall Wierenga , director of Ocera Therapeutics, Inc. purchased 5,000 shares on Jun 23, 2015.
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Linda Grais the President and CEO of Ocera Therapeutics Inc (NASDAQ:OCRX ...
Linda Grais, President and CEO of Ocera Therapeutics Inc (NASDAQ:OCRX) 3.63 +0.11 3.13% is the insider, Octafinance want to inform you about.
Analyst Rating Update on Ocera Therapeutics, Inc.
As many as 2 brokerage firms have rated Ocera Therapeutics, Inc. (NASDAQ:OCRX) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term.
Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) Rally 4.59%
Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) appreciated by 4.59% during the past week but lost 0.49% on a 4-week basis.
Ocera Therapeutics Reports Second Quarter 2015 Financial Results
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations.
Ocera Therapeutics (OCRX) Posts Quarterly Earnings Results, Misses Estimates ...  sleekmoney
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference
PALO ALTO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D.
Tranzyme Inc (OCRX) news: The Long-Term Risks About Ocera Therapeutics
The Long-Term Risks About Ocera Therapeutics. Introduction. Ocera Therapeutics (NASDAQ:OCRX) is a company with one main value driver, OCR002.